![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
CJ Meade, J Mierau, I Leon and HA Ensinger
Department of Biological Research, Boehringer Ingelheim KG, Germany.
Activation of the adenosine A3 receptor subtype by the agonist N6-2-(4- aminophenyl)ethyladenosine is shown here to induce bronchospasm (increased pulmonary resistance and decreased pulmonary compliance) in BDE strain rats. The effect is substantially reduced by pretreating the rats with compound 48/80, disodium cromoglycate (30 micrograms/kg) or epinastine (10 micrograms/kg), which is compatible with involvement of mast cells. It is also substantially reduced by combined vagotomy and atropinization or by pretreatment with the NK2 receptor antagonist L- 659,877, suggesting involvement of neuropeptide-mediated neural pathways. The mechanism by which activation of the adenosine A3 receptor induces bronchospasm is distinct from the mechanism by which activation of the adenosine A1 receptor induces bronchospasm. In particular, the A1 agonist 2-chloro-N6-cyclopentyladenosine can increase pulmonary resistance independently of mast cell activation. These results are in accord with the concept that a pathway exists in vivo by which activation of mast-like cells can activate axon reflexes, that adenosine acting through its A3 receptor can potentially up- regulate this pathway and that antiallergic substances such as disodium cromoglycate and epinastine may interfere with this pathway.
This article has been cited by other articles:
|
|
 |
|
  X. Hua, C. J. Erikson, K. D. Chason, C. N. Rosebrock, D. A. Deshpande, R. B. Penn, and S. L. Tilley Involvement of A1 adenosine receptors and neural pathways in adenosine-induced bronchoconstriction in mice Am J Physiol Lung Cell Mol Physiol, July 1, 2007; 293(1): L25 - L32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Chuaychoo, M.-G. Lee, M. Kollarik, R. Pullmann Jr, and B. J. Undem Evidence for both adenosine A1 and A2A receptors activating single vagal sensory C-fibres in guinea pig lungs J. Physiol., September 1, 2006; 575(2): 481 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Polosa Adenosine-receptor subtypes: their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease Eur. Respir. J., August 1, 2002; 20(2): 488 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Cronstein, M. C. Montesinos, and G. Weissmann Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappa B PNAS, May 25, 1999; 96(11): 6377 - 6381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes, K. F. Chung, and C. P. Page Inflammatory Mediators of Asthma: An Update Pharmacol. Rev., December 1, 1998; 50(4): 515 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. MEADE The Mechanism by Which Epinastine Stops an Adenosine Analog from Contracting BDE Rat Airways Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 522 - 530. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
